Novanta (NOVT) Stock Overview
Provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NOVT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novanta Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$155.71 |
| 52 Week High | US$165.56 |
| 52 Week Low | US$98.27 |
| Beta | 1.62 |
| 1 Month Change | 20.85% |
| 3 Month Change | 6.37% |
| 1 Year Change | 20.16% |
| 3 Year Change | -7.25% |
| 5 Year Change | 12.60% |
| Change since IPO | 876.99% |
Recent News & Updates
Recent updates
Narrative Update • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.Narrative Update • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.Narrative Update • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.Narrative Update • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.Narrative Update • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.Narrative Update • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).Narrative Update • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.Narrative Update • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.Narrative Update • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.Narrative Update • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).Narrative Update • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.Narrative Update • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.Analysis Article • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...Analysis Article • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...Seeking Alpha • Sep 29
Novanta: The Solution To Elevated Expectations Is Lower Prices
Summary Novanta Inc. remains a trusted technology partner for OEMs, but recent growth has been modest and organic performance underwhelming. Despite a strong track record and niche positioning, Novanta trades at a demanding 30x earnings multiple, currently posting quite flattish growth. Recent results show minimal sales and earnings growth, while NOVT leverage is set to rise due to a $200 million buyback program. I remain on the sidelines, seeking a lower entry point and a higher earnings yield to justify NOVT stock's premium and ensure a margin of safety. Read the full article on Seeking AlphaAnalysis Article • Sep 13
Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Narrative Update • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Analysis Article • Aug 29
Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 69.2x Novanta Inc. ( NASDAQ:NOVT ) may be sending very bearish signals at...Analysis Article • Jun 16
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for Novanta is US$95.22 based on 2 Stage Free Cash Flow to Equity Novanta is...Analysis Article • May 20
Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
New Narrative • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Shareholder Returns
| NOVT | US Electronic | US Market | |
|---|---|---|---|
| 7D | 14.3% | 5.5% | 1.1% |
| 1Y | 20.2% | 98.4% | 26.7% |
Return vs Industry: NOVT underperformed the US Electronic industry which returned 93.7% over the past year.
Return vs Market: NOVT underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 7.3% |
| Electronic Industry Average Movement | 8.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NOVT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NOVT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles.
Novanta Inc. Fundamentals Summary
| NOVT fundamental statistics | |
|---|---|
| Market cap | US$5.54b |
| Earnings (TTM) | US$53.72m |
| Revenue (TTM) | US$1.00b |
103.2x
P/E Ratio5.5x
P/S RatioIs NOVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVT income statement (TTM) | |
|---|---|
| Revenue | US$1.00b |
| Cost of Revenue | US$560.43m |
| Gross Profit | US$444.51m |
| Other Expenses | US$390.79m |
| Earnings | US$53.72m |
Last Reported Earnings
Apr 03, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 44.23% |
| Net Profit Margin | 5.35% |
| Debt/Equity Ratio | 18.4% |
How did NOVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 04:57 |
| End of Day Share Price | 2026/05/14 00:00 |
| Earnings | 2026/04/03 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novanta Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |